Projektdarstellungen auf der Webseite

Jedes von der Gebert Rüf Stiftung geförderte Projekt wird mit einer Webdarstellung zugänglich gemacht, die über die Kerndaten des Projektes informiert. Mit dieser öffentlichen Darstellung publiziert die Stiftung die erzielten Förderresultate und leistet einen Beitrag zur Kommunikation von Wissenschaft in die Gesellschaft.


DIATHERIS – For Better Therapy & Life of People with Type 1 Diabetes


The project management is responsible for the content of the information provided.


  • Projekt-Nr: GRS-061/23 
  • Förderbeitrag: CHF 150'000 
  • Bewilligung: 31.10.2023 
  • Dauer: 01.2024 - 06.2024 
  • Handlungsfeld:  InnoBooster, seit 2018



DIATHERIS is a spin-off of the University of Geneva with the goal of developing a groundbreaking therapeutic solution to improve the treatment of type 1 diabetes. Currently, insulin therapy stands as the sole option for type 1 diabetes (T1D) patients. However, this therapy has proven suboptimal, with a central challenge being the achievement of proper glycemic control without the associated risks of life-threatening hypoglycemia and ketoacidosis. Additionally, the lipogenic action of therapeutic insulin contributes to overweight, a significant factor in cardiovascular co-morbidities among T1D patients.
The existing strategies to enhance insulin therapy for T1D fall short of providing a satisfactory solution. While adjunct therapies improve hyperglycemia, they concurrently elevate the risk of life-threatening hypoglycemia and ketoacidosis—persistent challenges in T1D treatments. At Diatheris, we are actively developing a first-in-class therapeutic solution to overcome these limitations and enhance T1D management.
Our proprietary approach hinges on a small protein known as S100A9. The S100A9 treatment exploits an insulin-independent pathway, displaying remarkable results in combination with low-dose insulin. This combination works to improve glycemic control, effectively normalizing glycemia without the associated risks of hypoglycemia and ketoacidosis.


The Innobooster program is instrumental in developing a final drug formulation, enabling the initiation of regulatory toxicology studies necessary for a first-in-human clinical trial application.


Am Projekt beteiligte Personen

Giorgio Ramadori, project leader at University of Geneva

Letzte Aktualisierung dieser Projektdarstellung  15.07.2024